{"created":"2023-06-19T07:25:28.897588+00:00","id":13316,"links":{},"metadata":{"_buckets":{"deposit":"27ddbd45-aac0-49a9-a568-ea9a53c57a53"},"_deposit":{"created_by":47,"id":"13316","owners":[47],"pid":{"revision_id":0,"type":"depid","value":"13316"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00013316","sets":["212:262:306"]},"author_link":["20007","20008","20004","20006","20005"],"item_3_biblio_info_3":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-01-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"52","bibliographicPageStart":"49","bibliographicVolumeNumber":"72","bibliographic_titles":[{},{"bibliographic_title":"Die Pharmazie","bibliographic_titleLang":"en"}]}]},"item_3_text_4":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_text_value":"10.1691/ph.2017.6808"}]},"item_3_textarea_2":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_textarea_value":"BACKGROUND/AIM:\nThe effect of oral trifluridine-tipiracil (TAS-102)-induced neutropenia on survival of patients with advanced/recurrent colorectal cancer was investigated.\n\nPATIENTS AND METHODS:\nBetween August 2014 and May 2016, 41 patients underwent TAS-102 monotherapy at Ogaki Municipal Hospital. Risk factors for survival were examined by univariate and multivariate analyses.\n\nRESULTS:\nIn 41 patients, mild neutropenia (grade 1-2) occurred in 10 patients (24.4%), severe neutropenia (grade 3-4) occurred in 13 (31.7%), and 18 (43.9%) did not experience neutropenia. The median overall survival times in the absent, mild, and severe groups were 120 days (95% confidence interval [CI], 67-179), 184 days (95% CI, 94-274), and 299 days (95% CI, 192-404), respectively (p = 0.045). In patients with severe neutropenia, the death hazard ratio was 0.442 (95% CI, 0.201-0.974; p = 0.042).\n\nCONCLUSION:\nIn patients with advanced/recurrent colorectal cancer, TAS-102-induced severe neutropenia was associated with superior survival."}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy","subitem_title_language":"en"}]},"item_type_id":"3","owner":"47","path":["306"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-07-10"},"publish_date":"2018-07-10","publish_status":"0","recid":"13316","relation_version_is_last":true,"title":["Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy"],"weko_creator_id":"47","weko_shared_id":-1},"updated":"2023-06-19T08:57:02.371347+00:00"}